1. Poisonous snakebite in central Texas. Possible indicators for antivenin treatment.
- Author
-
White RR 4th and Weber RA
- Subjects
- Adolescent, Adult, Age Factors, Antivenins adverse effects, Blood Cell Count, Blood Coagulation Tests, Child, Child, Preschool, Crotalid Venoms, Female, Fluid Therapy, Humans, Infant, Infant, Newborn, Length of Stay, Male, Middle Aged, Recreation, Snake Bites pathology, Snake Bites surgery, Texas, Antivenins therapeutic use, Snake Bites therapy
- Abstract
Sixty-seven patients hospitalized for poisonous snakebite between 1975 and 1990 were managed by elevation, tetanus prophylaxis, intravenous fluids and antibiotics, and often by a limited excision of the bite site in the Emergency Department, with sequential laboratory studies as needed. Antivenin was used for systemic envenomation, and 23 of the 67 patients (34%) received 133 vials. Thirteen of the twenty-three patients (56%) had adverse reactions to the antivenin. Two significant observations arose. First age was an indicator. Eleven of eighteen patients 12 years or younger (61%) received antivenin, whereas 12 of 49 patients older than 12 years (24%) received antivenin (p = 0.0085, Fisher's exact test). Second species of snake was an indicator. Sixty-two snakes were identified (93%). Of 39 rattlesnake (Crotalus and Sistrurus) bites, 20 patients received antivenin (53%), but of 23 copperhead and water moccasin (Agkistrodon) bites, only three patients (12.5%) received antivenin (p = 0.0025). Antivenin may be indicated for use in systemic rattlesnake envenomation, especially in younger patients.
- Published
- 1991
- Full Text
- View/download PDF